Skip to content

Comparison of the effect of zingiber and acupressure on nausea and vomiting

Comparison of the effect of zingiber and acupressure onchemotherapy induced nausea and vomiting (CINV) in patients with breast cancer

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20120109008665N10
Enrollment
80
Registered
2019-11-24
Start date
2019-12-22
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nausea and Vomiting. Nausea with vomiting, unspecified

Interventions

Sponsors

Semnan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Detection of breast cancer by an oncologist and pathologist Age between 18 and 70 years The normal values of hematological and biochemical laboratory values in the Zingiber group The desire to participate in the study

Exclusion criteria

Exclusion criteria: Sensitivity to Zingiber and its consumption over the past week (at first use) The presence of sensitivity and ulcers or any skin problems at the site of use of acupressure wristband Use of blood diluent such as Aspirin, Warfarin, Heparin, Plavix and ... in the Zingiber group. Coagulation disorders (platelets less than 100,000/mm3, etc.) in the Zingiber group Receiving radiotherapy and chemotherapy simultaneously The diseases that lead to nausea and vomiting include liver, kidney, upper gastrointestinal cancer, acute hepatitis B, gastrointestinal obstruction, brain malignancies, high blood pressure, motion sickness, diabetes and electrolyte disorders such as hyponatremia and Hypokalemia Use of alcohol and opium The history of psychiatric problems in patients under treatment with acupressure wristband

Design outcomes

Primary

MeasureTime frame
Severity of nausea and vomiting. Timepoint: Evaluation and measurements will be performed from the first day of chemotherapy up to 5 days after the completion of chemotherapy by the patient. Method of measurement: Morrow Assessment of Nausea and Emesis (MANE).;Frequency of nausea and vomiting. Timepoint: Evaluation and measurements will be performed from the first day of chemotherapy up to 5 days after the completion of chemotherapy by the patient. Method of measurement: Morrow Assessment of Nausea and Emesis (MANE).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHassan Babamohamadi

Semnan University of Medical Sciences

babamohammady2007@gmail.com+98 23 3365 4192

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026